Handelsbanken Fonder Ab Arrowhead Pharmaceuticals, Inc. Transaction History

Handelsbanken Fonder Ab

$25.3 Billion
Q3 2024

A detailed history of Handelsbanken Fonder Ab transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Handelsbanken Fonder Ab holds 35,700 shares of ARWR stock, worth $751,485. This represents 0.0% of its overall portfolio holdings.

Number of Shares

35,700

Previous 30,500 17.05%

Holding current value

$751,485

Previous $793,000 12.74%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 04, 2024	BUY	$19.36 - $29.54 $100,672 - $153,608	5,200 Added 17.05%	35,700 $692,000
Q2 2024 Aug 05, 2024	BUY	$21.87 - $28.24 $164,025 - $211,800	7,500 Added 32.61%	30,500 $793,000
Q1 2024 May 13, 2024	BUY	$27.21 - $39.48 $38,094 - $55,271	1,400 Added 6.48%	23,000 $658,000
Q4 2023 Feb 01, 2024	BUY	$21.2 - $31.03 $31,800 - $46,545	1,500 Added 7.46%	21,600 $661,000
Q2 2023 Aug 02, 2023	BUY	$25.16 - $41.38 $77,996 - $128,278	3,100 Added 18.24%	20,100 $717,000
Q1 2022 May 11, 2022	SELL	$39.62 - $69.97 $122,821 - $216,907	-3,100 Reduced 15.42%	17,000 $782,000
Q4 2021 Feb 08, 2022	SELL	$58.09 - $82.51 $23,236 - $33,004	-400 Reduced 1.95%	20,100 $1.33 Million
Q3 2021 Nov 10, 2021	BUY	$58.38 - $84.96 $116,760 - $169,920	2,000 Added 10.81%	20,500 $1.28 Million
Q4 2020 Feb 11, 2021	BUY	$43.82 - $85.37 $118,314 - $230,499	2,700 Added 17.09%	18,500 $1.42 Million
Q2 2020 Aug 13, 2020	BUY	$26.12 - $43.27 $412,696 - $683,666	15,800 New	15,800 $682,000
Q1 2020 May 14, 2020	SELL	$20.56 - $63.12 $1.11 Million - $3.42 Million	-54,120 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$28.14 - $73.01 $1.52 Million - $3.95 Million	54,120 New	54,120 $3.43 Million

Others Institutions Holding ARWR

# of Institutions

295

Shares Held

91.1M

Call Options Held

155K

Put Options Held

426K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.23B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

News

Stay updated on Handelsbanken Fonder Ab with notifications on news.

Account

Handelsbanken Fonder Ab Arrowhead Pharmaceuticals, Inc. Transaction History